Lucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target
Ovid Therapeutics Inc. (NASDAQ:OVID) is among the best US stocks under $10 to invest in. Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc.
Ovid Therapeutics Inc. (OVID)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 3,853,818 | $1,271,375 | 0.05% | |
| 2. | Sio Capital Michael Castor | 2,232,000 | $736,337 | 0.28% | |
| 3. | Renaissance Technologies Jim Simons | 2,095,309 | $691,242 | +105% | 0% |
| 4. | Driehaus Capital Richard Driehaus | 1,400,191 | $461,923 | 0% | |
| 5. | Madison Avenue Partners Eli Samaha | 1,311,362 | $432,618 | -47% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.73 | 6,810 | $4,971.30 | 34,935 | 2025-01-27 | Filing | |
| $2.76 | 18,248 | $50,364.48 | 3,616,715 | 2024-03-18 | Filing | |
| $5.84 | 8,488 | $49,569.92 | 5,792,530 | 2020-08-28 | Filing | |
| $2.50 | 2,000,000 | $5,000,000.00 | 5,750,000 | 2019-10-08 | Filing | |
| $2.50 | 60,000 | $150,000.00 | 4,736,529 | 2019-10-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.56 | 5,279 | $2,956.24 | 73,406 | 2025-02-26 | Filing | |
| $0.56 | 3,902 | $2,185.12 | 67,973 | 2025-02-26 | Filing | |
| $2.15 | 17,344 | $37,289.60 | 0 | 2022-09-12 | Filing | |
| $3.71 | 34,017 | $126,203.07 | 726,823 | 2021-07-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,531,996 | $2,485,380 | 12.71% | |
| 2. | 2,636,115 | $869,918 | 0% | |
| 3. | 1,502,329 | $495,618 | 0.01% | |
| 4. | 1,369,010 | $451,636 | 0% | |
| 5. | 763,114 | $251,751 | 0% |
News See All
8 Best US Stocks Under $10 to Invest in
Everyone seeks a stock that has good upside potential, but a stock that is cheap and has good prospects - that’s what a steal deal looks like.
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best penny stocks under $1 to buy now. On June 25, Ovid Therapeutics announced a definitive agreement with Immedica Pharma AB.
12 Best Penny Stocks Under $1 to Buy Now
On July 18, Greg Tuorto of Goldman Sachs joined CNBC's 'Closing Bell' to state that the small-cap market is starting to show signs of life.
5 Oversold Biotech Stocks To Buy Right Now
In this article, we will be taking a look at 5 oversold biotech stocks to buy right now.
20 Countries With Highest Rate of Epilepsy
In this article, we will take a detailed look at the 20 countries with the highest rates of epilepsy with insights into number of epilepsy cases by country and population.
5 Best Biotech Stocks to Buy Under $10
Ovid Therapeutics Inc. (NASDAQ:OVID) is an emerging biotech company that designs therapies for epilepsies, seizure-related disorders, and neurological disorders.
10 Best Biotech Stocks Under $10
In this article, we will look at the 10 best biotech stocks under $10.
Timothy P. Lynch's Stonepine Capital Portfolio: Top 5 Healthcare Stocks
In this article, we discuss the top 5 healthcare stock picks of Timothy P. Lynch's Stonepine Capital. If you want our detailed analysis of these stocks, go directly to Timothy P.
5 Pharmaceutical Stocks to Buy According to Timothy Lynch's Stonepine Capital
In this article, we will discuss the 5 pharmaceutical stocks to buy according to Timothy Lynch's Stonepine Capital based on Q2 2021 holdings of the fund.
Billionaire Hedge Funds
